Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04581330 · ClinicalTrials.gov registry record · NA

The Effects of Fractional CO2 Laser on Poikiloderma of Civatte

A NA study, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
NA
Development phase
10
Enrollment target

NCT04581330 is a NA study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04581330, a NA study, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target

Study Summary

This study will assess the safety and efficacy of fractional CO2 laser treatment for Poikiloderma of Civatte (POC).POC is a chronic vascular and pigmentary disorder typically involving the lateral and inferior neck region, as well as the chest area. Clinically, poikiloderma appears as a combination of telangiectasia, irregular pigmentation, and atrophic changes.Little data exist regarding the use of fractional CO2 laser for management of POC. This study hopes to fulfill this purpose. The primary outcome will be a blinded assessment by dermatologists in the improvement in POC using the Physician's Global Aesthetic Improvement Scale following therapy. The secondary outcomes include subject satisfaction post-treatment and assessment of all procedure-related adverse events.

Interventions

  • DEVICE DEKA SmartXide C02 laser

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2021-04-01
Est. Completion 2022-01-01
Phase NA

What the Registry Record Tells You About NCT04581330

The ClinicalTrials.gov registry entry for NCT04581330 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which DEKA SmartXide C02 laser is the first listed.

NCT04581330 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04581330 about?

NCT04581330 is a clinical study titled "The Effects of Fractional CO2 Laser on Poikiloderma of Civatte". This study will assess the safety and efficacy of fractional CO2 laser treatment for Poikiloderma of Civatte (POC).POC is a chronic vascular and pigmentary disorder typically involving the lateral and inferior neck region, as well as the chest area. Clinically, poikiloderma appears as a combination ...

What is the current status of trial NCT04581330?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2021-04-01. Estimated completion is 2022-01-01.

What interventions are being tested in trial NCT04581330?

The interventions under investigation include: DEKA SmartXide C02 laser (DEVICE).

Who is sponsoring clinical trial NCT04581330?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.